Mostrando 1 - 7 Resultados de 7 Para Buscar 'Cortés, J', tiempo de consulta: 4.04s Limitar resultados
2
artículo
Genetic Variation in Coat Colour Genes MC1R and ASIP Provides Insights Into Domestication and Management of South American Camelids
Publicado por
Marin, JC, Rivera, R, Varas, V, Cortes, J, Agapito, A, Chero, A, Chavez, A, Johnson, WE, Orozco-terWengel, P
Publicado 2018 Enlace
This research was supported by FONDECYT, Chile Grant 1140785, Postdoctoral Grant 3050046 and CONICYT Chile (Beca de Apoyo a Tesis Doctoral), Morris Animal Foundation (D05LA-002), Darwin Initiative for the Survival of Species (United Kingdom) 1312 grant 162/06/126, The British Embassy (Lima), NERC 1313 (United Kingdom) grant GST/02/828, and Newton Fund Researcher Links Travel grant (ID: RLTG9-LATAM-359537872) funded by the UK Department for Business, Energy and Industrial Strategy and CONCYTEC (Peru) and delivered by the British Council.
Agregar a favoritos
Guardado en:
3
artículo
Phylogeography and Population Genetics of Vicugna vicugna: Evolution in the Arid Andean High Plateau
Publicado por
Gonzalez, BA, Vasquez, JP, Gomez-Uchida, D, Cortes, J, Rivera, R, Aravena, N, Chero, AM, Agapito, AM, Varas, V, Wheleer, JC, Orozco-terWengel, P, Marin, JC
Publicado 2019 Enlace
In Peru, research was supported by Darwin Initiative for the Survival of Species (United Kingdom) grant 162/06/126 (1997-2000), The British Embassy (Lima), NERC (United Kingdom) grant GST/02/828 (1994-1998), the European Commission INCO-DC ICA4-2000-10229, MACS (2001-2005), and a Newton Fund Researcher Links Travel grant (ID: RLTG9-LATAM-359537872) funded by the United Kingdom Department for Business, Energy and Industrial Strategy and CONCYTEC (Peru) and delivered by the British Council; Asociacion Ancash, Peru (2004); FINCyT Peru grant 006-FINCyT-PIBAP-2007 (2008-2010); and COLP, Compania Operadora de LNG del Peru contract PLNG-EV-09012 (2010-2011).
Agregar a favoritos
Guardado en:
4
artículo
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
Publicado por
Turner, NC, Oliveira, M, Howell, SJ, Dalenc, F, Cortes, J, Gomez-Moreno, HL, Hu, X, Jhaveri, K, Krivorotko, P, Loibl, S, Morales-Murillo, S, Okera, M, Park, YH, Sohn, J, Toi, M, Tokunaga, E, Yousef, S, Zhukova, L, De-Bruin, EC, Grinsted, L, Schiavon, G, Foxley, A, Rugo, HS
Publicado 2023 Enlace
Background AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced breast cancer are limited. Methods In a phase 3, randomized, double-blind trial, we enrolled eligible pre-, peri-, and postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who had had a relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. Patients were randomly assigned in a 1:1 ratio to receive capivasertib plus fulvestrant or placebo plus fulvestrant. The dual primary end point was investigator-assessed progression-free survival assessed both in the overal...
Agregar a favoritos
Guardado en:
5
artículo
Guía de práctica clínica basada en la evidencia para el manejo de la sedoanalgesia en el paciente adulto críticamente enfermo
Publicado por
Celis-Rodríguez, Edgar, Birchenall, Claudia, de la Cal, Miguel Ángel, Castorena-Arellano, Guillermo Alberto, Hernández, Antonio, Ceraso, Daniel H., Díaz Cortés, J. C., Dueñas Castell, Carmelo, Jimenez, Edgar J., Meza, J. C., Muñoz-Martínez, Tomás, Sosa-García, Jesús Ojino, Pacheco Tovar, C., Pálizas, Fernando J., Pardo-Oviedo, Juan M., Pinilla, Darío I., Raffan-Sanabria, Fernando, Raimondi, Néstor O., Shinotsuka, Cláudia Righy, Suárez, Marta, Ugarte, Sebastián U., Rubiano, Sandra
Publicado 2013 Enlace
ABSTRACT Introduction Optimal management of sedation, analgesia and delirium offers comfort and security for the critical care patient, allows support measures to be applied more easily and enables an integral approach of medical care, but at the same time lowers the incidence of complications, which translates in better patient outcomes. Objective To update the Guía de práctica clínica basada en la evidencia para el manejo de la sedoanalgesia en el paciente adulto críticamente enfermo published in Medicina Intensiva in 2007, and give recommendations for the management of sedation, analgesia, and delirium. Methodology A group of 21 intensivists from 9 countries of the Federación Panamericana e Ibérica de Sociedades de Medicina Crítica y Terapia Intensiva, 3 of them also specialists in clinical epidemiology and methodology, gathered for the development of guidelines. Assessment of ...
Agregar a favoritos
Guardado en:
6
artículo
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Publicado por
Sharma, P, López-Tarruella, S, García-Saenz, JA, Khan, QJ, Gómez, HL, Prat, A, Moreno, F, Jerez-Gilarranz, Y, Barnadas, A, Picornell, AC, Monte-Millán MD, González-Rivera, M, Massarrah, T, Pelaez-Lorenzo, B, Palomero, MI, González Del Val, R, Cortés, J, Fuentes-Rivera H, Morales, DB, Márquez-Rodas, I, Perou, CM, Lehn, C, Wang, YY, Klemp, JR, Mammen, JV, Wagner, JL, Amin, AL, O'Dea, AP, Heldstab, J, Jensen, RA, Kimler, BF, Godwin, AK, Martín, M
Publicado 2018 Enlace
Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC. Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence of invasive tumor in breast and axilla) and Residual cancer burden (RCB) were evaluated. Patients were followed for recurrence and survival. Extent of pathologic response was associated with RFS and OS using the Kaplan-Meier method. Results: Median age was 51 years, and 52% were node-positive. pCR and ...
Agregar a favoritos
Guardado en:
7
artículo
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Publicado por
Cardoso, F, Paluch-Shimon, S, Senkus, E, Curigliano, G, Aapro, MS, André, F, Barrios, CH, Bergh, J, Bhattacharyya, GS, Biganzoli, L, Boyle, F, Cardoso, MJ, Carey, LA, Cortés, J, El Saghir, NS, Elzayat, M, Eniu, A, Fallowfield, L, Francis, PA, Gelmon, K, Gligorov, J, Haidinger, R, Harbeck, N, Hu, X, Kaufman, B, Kaur, R, Kiely, BE, Kim, SB, Lin, NU, Mertz, SA, Neciosup, SO, ffersen, BV, Ohno, S, Pagani, O, Prat, A, Penault-Llorca, F, Rugo, HS, Sledge, GW, Thomssen, C, Vorobiof, DA, Wiseman ,T, Xu, B, Norton, L, Costa, A, Winer, EP
Publicado 2020 Enlace
This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients. It provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care. Updated diagnostic and treatment algorithms are also provided. All recommendations were compiled by a multidisciplinary group of international experts. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.
Agregar a favoritos
Guardado en: